Multi-component infusion hepatoprotectors for liver damage

Drug-induced liver injuries (DILI) remain today one of the most pressing problems not only in gastroenterology, but also in all therapy. Up to 10% of the changes in laboratory parameters can be attributed to the use of drugs. The importance of DILI has increased significantly in recent years, due to...

Full description

Bibliographic Details
Main Authors: E. I. Sas, V. B. Grinevich
Format: Article
Language:Russian
Published: Remedium Group LLC 2019-05-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/3009
id doaj-3b6ab065fbbc46dfb35c367c043b87f5
record_format Article
spelling doaj-3b6ab065fbbc46dfb35c367c043b87f52021-07-28T13:29:41ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-05-0103848810.21518/2079-701X-2019-3-84-882928Multi-component infusion hepatoprotectors for liver damageE. I. Sas0V. B. Grinevich1Federal State Budgetary Military Educational Institution of Higher Education «Military Medical Academy named after S.M. Kirov» of the Ministry of Defense of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education «St. Petersburg State Pediatric Medical University» of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Higher Education «St. Petersburg State Pediatric Medical University» of the Ministry of Health of the Russian FederationDrug-induced liver injuries (DILI) remain today one of the most pressing problems not only in gastroenterology, but also in all therapy. Up to 10% of the changes in laboratory parameters can be attributed to the use of drugs. The importance of DILI has increased significantly in recent years, due to the increase in the number of over-the-counter medicines on the pharmaceutical market, as well as non-compliance with the methods and modes of administration. There are common links in the pathogenesis of DILI, including hypoxia, de-energization (deficit of ATP production), damage to hepatocyte membranes and suppression of antioxidant protection. Therefore, pathogenetic pharmacotherapy and prevention of liver damage are based on drugs with an action mechanism aimed at eliminating one or more links in the pathogenesis. One of these drugs is Remaxol, which includes antihypoxantantioxidants of metabolic type: natural metabolites, substrates and cofactors involved in energy metabolism. Remaxol was administered to 30 patients with duodenal ulcer (DU) in the acute phase in addition to the main eradication therapy in the case of cytolytic syndrome by the end of the first week of therapy intravenously dripping at a rate of 40-60 drops/min in a daily dose of 400 ml for 10 days a day. Against the background of Remaxol application, the patients with DILI had stabilization of the main biochemical parameters: the level of AST, ALT, direct bilirubin, GGT and alkaline phosphatase. These changes were accompanied by a positive dynamics of the general state of health. The use of Remaxol in patients with DILI will allow to achieve clinical and biochemical remission, preventing the development of severe liver damage, and contributes to the preservation of the recommended duration of treatment of the underlying disease.https://www.med-sovet.pro/jour/article/view/3009drug-induced liver injuryside effectamber acidremaxol
collection DOAJ
language Russian
format Article
sources DOAJ
author E. I. Sas
V. B. Grinevich
spellingShingle E. I. Sas
V. B. Grinevich
Multi-component infusion hepatoprotectors for liver damage
Медицинский совет
drug-induced liver injury
side effect
amber acid
remaxol
author_facet E. I. Sas
V. B. Grinevich
author_sort E. I. Sas
title Multi-component infusion hepatoprotectors for liver damage
title_short Multi-component infusion hepatoprotectors for liver damage
title_full Multi-component infusion hepatoprotectors for liver damage
title_fullStr Multi-component infusion hepatoprotectors for liver damage
title_full_unstemmed Multi-component infusion hepatoprotectors for liver damage
title_sort multi-component infusion hepatoprotectors for liver damage
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2019-05-01
description Drug-induced liver injuries (DILI) remain today one of the most pressing problems not only in gastroenterology, but also in all therapy. Up to 10% of the changes in laboratory parameters can be attributed to the use of drugs. The importance of DILI has increased significantly in recent years, due to the increase in the number of over-the-counter medicines on the pharmaceutical market, as well as non-compliance with the methods and modes of administration. There are common links in the pathogenesis of DILI, including hypoxia, de-energization (deficit of ATP production), damage to hepatocyte membranes and suppression of antioxidant protection. Therefore, pathogenetic pharmacotherapy and prevention of liver damage are based on drugs with an action mechanism aimed at eliminating one or more links in the pathogenesis. One of these drugs is Remaxol, which includes antihypoxantantioxidants of metabolic type: natural metabolites, substrates and cofactors involved in energy metabolism. Remaxol was administered to 30 patients with duodenal ulcer (DU) in the acute phase in addition to the main eradication therapy in the case of cytolytic syndrome by the end of the first week of therapy intravenously dripping at a rate of 40-60 drops/min in a daily dose of 400 ml for 10 days a day. Against the background of Remaxol application, the patients with DILI had stabilization of the main biochemical parameters: the level of AST, ALT, direct bilirubin, GGT and alkaline phosphatase. These changes were accompanied by a positive dynamics of the general state of health. The use of Remaxol in patients with DILI will allow to achieve clinical and biochemical remission, preventing the development of severe liver damage, and contributes to the preservation of the recommended duration of treatment of the underlying disease.
topic drug-induced liver injury
side effect
amber acid
remaxol
url https://www.med-sovet.pro/jour/article/view/3009
work_keys_str_mv AT eisas multicomponentinfusionhepatoprotectorsforliverdamage
AT vbgrinevich multicomponentinfusionhepatoprotectorsforliverdamage
_version_ 1721273804287639552